文献速递眼底病与葡萄膜炎

法瑞西单抗相关的无菌性眼内炎症

Sterile Intraocular Inflammation Associated With Faricimab.
PubMed 文献 · JAMA Ophthalmol · 2024-10-10

该研究回顾了瑞士一家学术型三级转诊中心在2022年6月1日至2024年3月5日期间转诊的、接受法瑞西单抗玻璃体腔注射后不久出现眼内炎症的患者,共纳入7例患者12只眼。中位注射3.5次后发生眼内炎症,2只眼出现视网膜血管炎,其中1只眼为闭塞性动脉和静脉血管炎,导致黄斑毛细血管无灌注及视力从20/80不可逆下降至20/2000;其余眼表现为中度前节炎症,无明显视力变化。作者认为这些发现不能证明因果关系,仅能生成未来研究假设,并提示对接受法瑞西单抗治疗的患者进行持续监测的重要性。

要点

  • 7例患者12只眼在玻璃体腔注射法瑞西单抗后出现非感染性眼内炎症。
  • 2只眼出现视网膜血管炎,其中1只眼为闭塞性血管炎并导致视力从20/80降至20/2000。
  • 眼内炎症发生于中位3.5次注射后,距末次注射中位28天,3只眼眼压≥30 mmHg。

核心结论

  • 该病例系列强调法瑞西单抗治疗相关眼内炎症虽罕见但可能严重。
  • 这些发现不能证明因果关系,只能为未来研究生成假设。
  • 结果提示对接受法瑞西单抗治疗的患者进行持续监测以及时识别和管理潜在不良事件的重要性。

研究设计与样本

  • 这是一项观察性病例系列的回顾性分析,起始于2024年4月。
  • 患者来自瑞士一家学术型三级转诊中心。
  • 纳入2022年6月1日至2024年3月5日期间接受法瑞西单抗玻璃体腔注射后不久因眼内炎症被转诊的患者。
  • 暴露为法瑞西单抗6 mg(120 mg/mL溶液0.05 mL),用于新生血管性年龄相关性黄斑变性或糖尿病性黄斑水肿。

主要发现

  • 共识别7例患者12只眼(平均[SD]年龄73.3[16.7]岁;女性4例[57.1%])在22个月内于玻璃体腔注射法瑞西单抗后出现非感染性眼内炎症。
  • 2只眼出现视网膜血管炎并伴有前节和后节炎症,其中1只眼为闭塞性动脉和静脉血管炎,导致黄斑毛细血管无灌注及视力从20/80不可逆下降至20/2000。
  • 其余眼表现为中度前节炎症,无明显视力变化。
  • 眼内炎症事件发生于中位(IQR)3.5(2.0-4.3)次法瑞西单抗注射后。
  • 末次法瑞西单抗注射与炎症诊断之间的中位(IQR)间隔为28(24-38)天;3只眼发现眼压升高至30 mmHg或更高。

临床怎么用

  • 作者认为这些结果提示对接受法瑞西单抗治疗的患者进行持续监测以及时识别和管理潜在不良事件的重要性。

局限性

  • 这些发现不能证明因果关系,只能为未来研究生成假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials are conducted to establish both drug safety and efficacy. However, evidence of adverse events associated with these drugs in the clinical practice setting can be of value at generating hypotheses regarding less common safety issues, even if causality cannot be determined. OBJECTIVE: To present and analyze cases of intraocular inflammation associated with faricimab therapy in patients referred to a single European institution. DESIGN, SETTING, AND PARTICIPANTS: This was a review starting in April of 2024 of an observational case series. Patients were from a single academic-based tertiary referral center in Switzerland. Included in the analysis were patients referred for intraocular inflammation soon after receiving a faricimab intravitreal injection between June 1, 2022, and March 5, 2024. EXPOSURE: Faricimab, 6 mg (0.05 mL of a 120-mg/mL solution), administrated for neovascular age-related macular degeneration or diabetic macular edema. MAIN OUTCOMES AND MEASURES: The systemic and ocular histories and imaging data available were reviewed. The following were evaluated: visual acuity measured with habitual correction using the Early Treatment of Diabetic Retinopathy Study charts before and after the event; intraocular pressure; patient symptoms; anterior, intermediate, or posterior location of the intraocular inflammation; and the presence of retinal vasculitis. Multimodal imaging including color fundus photographs, fluorescein angiograms, indocyanine green angiograms, and optical coherence tomography were reviewed. RESULTS: A total of 12 eyes from 7 patients (mean [SD] age, 73.3 [16.7] years; 4 female [57.1%]) over 22 months were identified as having noninfectious intraocular inflammation after intravitreal faricimab injections. Among these cases, in 2 eyes, retinal vasculitis was present together with anterior and posterior inflammation. One of the 2 eyes had an occlusive form of vasculitis of the arteries and veins, leading to subsequent macular capillary nonperfusion and clinically relevant irreversible vision deterioration from 20/80 to 20/2000. The remaining eyes were characterized by moderate anterior segment inflammation without substantial vision changes. The intraocular inflammation event occurred after a median (IQR) of 3.5 (2.0-4.3) faricimab injections. The median (IQR) interval between the last faricimab injection and the diagnosis of inflammation was 28 (24-38) days. Increased intraocular pressure of 30 mm Hg or higher was found in 3 eyes. CONCLUSIONS AND RELEVANCE: This case series highlights the occurrence of rare, but potentially severe, intraocular inflammation associated with faricimab therapy. Although these findings do not prove causality and can only generate hypotheses for future investigations, these results suggest the importance of continuous surveillance and monitoring for patients undergoing faricimab therapy to promptly identify and manage potential adverse events.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cozzi M, Ziegler A, Fasler K, et al. Sterile Intraocular Inflammation Associated With Faricimab. JAMA Ophthalmol. 2024. PMID: 39388167. doi:10.1001/jamaophthalmol.2024.3828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。